Fidelity Management & Research Company and OrbiMed led a $81m Series B round in Evozyne.

Fidelity Management & Research Company, an American multinational financial services corporation, and OrbiMed, an investment company focused on healthcare, led a $81m Series B round in Evozyne, a biotechnology company that specializes in protein design and molecular scale, with participation from NVentures, Paragon Biosciences and Valor Equity Partners. “In its first three years, Evozyne proved it could deliver novel, high-performance proteins that solve critical problems in healthcare and sustainability. Our next three years will be tightly focused on maximizing our generative AI platform for drug development and carbon capture, while we develop a portfolio of gene editors and enzymes that modulate immune response,” Mike Gamson, Evozyne CEO.